SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 million of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of sha ...

SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company's expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business. "We have enjoyed a longstanding relation ...

SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) today, May 17th, 2024 at the Mission Bay Conference Center in San Francisco. This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update the ...

Core Insights - Cytokinetics is hosting the Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) to foster collaboration and innovation in muscle biology research [1][2] - The company is focused on developing first-in-class muscle activators and next-in-class muscle inhibitors for treating diseases related to cardiac muscle performance [3] Company Overview - Cytokinetics is a late-stage biopharmaceutical company specializing in cardiovascular treatments, particularly targeting muscle performance [3] - The company is preparing for regulatory submissions for aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [3] - Other ongoing clinical trials for aficamten include MAPLE-HCM, ACACIA-HCM, CEDAR-HCM, and FOREST-HCM, focusing on various patient populations with hypertrophic cardiomyopathy [3] - Cytokinetics is also developing omecamtiv mecarbil for heart failure and CK-586 and CK-136 for different types of heart failure [3] Event Details - The CLIMB symposium aims to bring together scientists and researchers to share innovative research and promote interdisciplinary dialogue in muscle biology [2] - The event features expert speakers and poster presentations, enhancing networking opportunities within the muscle biology community [2][4]

Title: Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Substudy Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University Date: Augst 30, 2024 Topic: Infiltrative Myocardial Disease Session Title: Cardiac Amyloidosis: Diagnosis and Outcomes Session Type: Moderated ePosters Session Time: 3:00-3:50 PM BST Location: Station 10 Title: Clinical Application of Biomarkers in ...

Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongly Correlated to Other Measures of Clinical Improvement Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 94-3291317 (State or other jur ...

Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Diane Weiser - SVP of Corporate Communication and IR Robert Blum - President and CEO Fady Malik - EVP of R&D Stuart Kupfer - SVP and Chief Medical Officer Andrew Callos - EVP and Chief Commercial Officer Robert Wong - VP and Chief Accounting Officer Conference Call Participants Paul Choi - Goldman Sachs Srikripa Devarakonda - Truist Securities Tessa Romero - JPMorgan Roanna Ruiz - Leerink Sa ...

Cytokinetics (CYTK) came out with a quarterly loss of $1.33 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -14.66%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.03 per share when it actually produced a loss of $1.38, delivering a surprise of -33.98%.Over the last four quarters, the com ...

SOUTH SAN FRANCISCO, Calif., May 8, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $135.6 million, or $1.33 per share, compared to net loss for the first quarter of 2023 of $131.3 million, or $1.38 per share. Cash, cash equivalents and investments totaled $634.3 million at March 31, 2024. "In the first quarter, we advanced our muscle-biology portfolio anchored by the broad development program of aficamten. In para ...